Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 24, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/24/14 - BRIEF: Coral Gables drug company to make new medicine available at no cost [The Miami Herald :: ]
April 23 Coral Gables- based Catalyst Pharmaceutical Partners soon will make its investigational drug Firdapse available at no cost to patients with a certain autoimmune disorder. Catalyst said it expects to submit an application for Firdapse's approval with the U.S. Food and Drug Administration next year. Catalyst has been leading the developmen
4/23/14 - "Non-Enteric Coated Pharmaceutical Composition and Use Thereof" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, Wen Jen; Alai, Milind, filed on September 28, 2012, was made available online on April 10, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan University.
4/23/14 - "Optimal Management of Lung Function Data" Webinar Provides Insight to Drive More Successful Respiratory Clinical Trial Outcomes
By a News Reporter-Staff News Editor at Biotech Week Respiratory experts Phil Lake, Ph.D., of Theorem Clinical Research and Jim Sowash from ERT will present a live, interactive webinar titled "Optimal management of lung function data to drive successful respiratory clinical trial outcomes" at 10 a.m. EDT on Wednesday, April 23. "Variability in l
4/23/14 - AbbVie to Present Data on Investigational Compounds at the 2014 American Society of Clinical Oncology Annual Meeting
AbbVie today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50 th Annual Meeting of the American Society of Clinical Oncology, May 30- June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative therapies that improve
4/23/14 - ABLYNX ANNOUNCES WARRANT EXERCISE
As a result of this transaction, Ablynx now has 49,083,327 shares outstanding. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncolog
4/23/14 - ABLYNX INITIATES PHASE I BIOAVAILABILITY STUDY WITH SUBCUTANEOUS FORMULATION OF ITS ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE
Ablynx today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of the evaluation of a subcutaneous formulation of its anti-IL-6R Nanobody , ALX-0061, for the treatment of inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus. In September 2013, Ablynx and
4/23/14 - Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with...
4/23/14 - Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox
By a News Reporter-Staff News Editor at Biotech Week ACCESS PHARMACEUTICALS, INC. provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard?, for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved a
4/23/14 - Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology 66 th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA.. The poster presentation will take place during Poster Session IV on Wednesday, April 30, 2014, from 7:30 to 11:00 a.m. The EASED study inves
4/23/14 - Aerpio Therapeutics Closes $22M Financing
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it closed a $22 M financing round led by new investor OrbiMed, with existing investors Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon
4/23/14 - Akorn Purchases Hi-Tech Pharmacal [Health & Beauty Close - Up]
Akorn, Inc., a niche pharmaceutical company, announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. According to a release, the combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. This combination also brings critical mass
4/23/14 - Alder Biopharma Reports Data from PoC Clinical Trial of ALD403, Will Be Presented at AANM
Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-conce
4/23/14 - Alzheimer's Drug Discovery Foundation Launches New Cognitive Vitality Site to Meet Critical Need in Alzheimer's Prevention and Education
NEW YORK, April 23, 2014/ PRNewswire-USNewswire/ The Alzheimer's Drug Discovery Foundation announced today the launch of Cognitive Vitality, a new online resource developed to provide a comprehensive and credible overview and analysis of the science for specific strategies to prevent Alzheimer's and related dementias. "Although there has been...
4/23/14 - Animal medicines a winning deal for drug makers [The Indianapolis Star :: ]
That's why Eli Lilly and Co. is plunking down big bucks to bulk up its animal health business as its overall sales have begun to flatten, mostly because of patent expirations on blockbuster drugs. "The growth is being fueled by the demand for protein in emerging markets and increased spending on pets in the U.S. and Europe," said Linda Bannister,
4/23/14 - Arca Biopharma, Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933 (Apr. 4, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arca Biopharma, Inc. was posted on April 4, 2014. The SEC file number is 0001193125-14-131643.. A U.S. Securities and Exchange Commission filing is a formal
4/23/14 - Array Biopharma Announces Binimetinib Continues to Advance in Clinical Development
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib, including obligations relating to...
4/23/14 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Apr. 3, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on April 3, 2014. The SEC file number is 0001127602-14-014048.. A U.S. Securities and Exchange Commission filing is a formal
4/23/14 - Assembly Pharmaceuticals and BioCrossroads Announce Investment to Advance Potentially Curative Therapy for Chronic Hepatitis B Virus
By a News Reporter-Staff News Editor at Biotech Week Assembly Pharmaceuticals and BioCrossroads announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly Pharmaceuticals is applying its novel science to develop agents with the potential to cure chronic HBV. Assembly Pharmaceuticals was form
4/23/14 - Avedro Announces Canadian Approval for its KXL II ? Advanced Cross-Linking System
Avedro Inc., a Boston- based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company s KXL II System. David Muller, PhD, CEO of Avedro states, With this approval of the KXL II, Canada joins the 28 members of the European Union that have received the CE mark and approval to use this advanced t
4/23/14 - Baxter Announces FDA Approval of ADVATE (Antihemophilic Factor [Recombinant]) with BAXJECT III Reconstitution System
Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. ''ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment with fewer steps
4/23/14 - BioAgilytix Labs Welcomes Dr. Dominique Gouty as Vice President of Business Operations [Global Data Point]
Bringing with her over 20 years of industry experience and a career spanning R %7 ED, clinical operations, and manufacturing in several multi-national pharmaceutical organizations such as Eli Lilly and Johnson %7 E Johnson, as well as smaller biotech companies and CROs, Dr. She has extensive experience ensuring strict GLP compliance for bioanalytic
4/23/14 - BioAlliance Pharma: DSMB Recommends Continuation of Phase III Clinical Trial [Health & Beauty Close - Up]
BioAlliance Pharma, a Company specialized in the development of drugs in orphan oncology diseases, said that the European Independent Board of Experts, in charge of the safety profile of the ReLive Phase III trial, held its fourth meeting and once more unanimously recommended continuing the study without modification. The trial is still expanding i
4/23/14 - BioLineRx Secures Approval for Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment [Professional Services Close - Up]
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's...
4/23/14 - Calgary Scientific Receives FDA Clearance for Mobile Diagnosis on all Modalities
By a News Reporter-Staff News Editor at Biotech Week Calgary Scientific Inc., a company known for creating transformative technology for the medical industry and beyond, announced their latest Class II clearance from the United States Food and Drug Administration. Calgary Scientific worked closely with a number of Radiologists at a world renowned
4/23/14 - CANNABIS SCIENCE, INC. - 10-K - MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This report contains forward looking statements within the meaning of Section 27 A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended. The Company's actual results could differ materially from those set forth on the forward looking statements as a result of the risks set forth in the Compa
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415